Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $17.1400 (0%) ($16.6900 - $17.7200) on Mon. Feb. 1, 2016. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 11.31% (three month average) | RSI | 28 | Latest Price | $17.1400(0%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -4.4% a day on average for past five trading days. | Weekly Trend | ADMS declines -13.9% a week on average for past two weeks. | Market Behavior | Normal for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(35%) IBB(33%) ARKG(25%) IWO(23%) IWM(22%) | Factors Impacting ADMS price | ADMS will decline at least -5.655% in a week (0% probabilities). VIXM(-15%) UUP(-8%) BNDX(-8%) TLT(-7%) SHY(-7%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -5.655% (StdDev 11.31%) | Hourly BBV | 0 () | Intraday Trend | 0.4% | | | |
|
1 - 5 Day Possible Target | $-4.42(-125.79%) | Resistance Level | $22.16 | 5 Day Moving Average | $18.11(-5.36%) | 10 Day Moving Average | $19.74(-13.17%) | 20 Day Moving Average | $22.16(-22.65%) | To recent high | -44.4% | To recent low | 15.9% | Market Cap | $485m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |